Influence of tetrachlorodecaoxide (Ryoxon) on the development of leukemia after total-body gamma-irradiation.
The effect of tetrachlorodecaoxide (TCDO) treatment after total-body irradiation (TBI) with gamma-rays (single dose, about LD 50) on the development of radiation-induced leukemia was tested in rats. TCDO was applied intravenously from day 4 through day 11. The control group was exposed to the same dosage of X-rays (TBI), but received physiological saline solution instead of TCDO. Compared to the control group, TCDO therapy initially markedly increased the survival rate: 72 versus 44% (6 months after TBI) and 36 versus 20% (1-year survival rate). The overall survival, however, was not significantly prolonged. TBI caused leukemia in 36% of the rats in the irradiation control group without TCDO treatment, however, none of 24 rats treated with TCDO after X-ray exposure developed leukemia. Since in this study TCDO was only administered for 8 days during the acute phase of radiation syndrome, we suppose that additional TCDO treatment at various times later on would lead to even better results.
Kempf
S R
SR
Institute of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg.
Blaszkiewitz
K
K
Port
R E
RE
Ivankovic
S
S
D000818:Animals; D002713:Chlorine / Q000627:therapeutic use*; D005720:Gamma Rays; D007953:Leukemia, Radiation-Induced / Q000517:prevention & control*; D008297:Male; D010087:Oxides / Q000627:therapeutic use*; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D051381:Rats; D014916:Whole-Body Irradiation / Q000009:adverse effects*
D010087:Oxides; D011837:Radiation-Protective Agents; D002713:Chlorine; C041955:tetrachlorodecaoxide